Ovulation rate per woman fParticipants with BMI < 30 kg/m2 · women with polycystic ovary syndrome
Metformin showed no clear difference in ovulation rate per woman Participants with BMI < 30 kg/m2b compared with clomiphene citrate (low certainty).
Gastrointestinal adverse events · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Ovulation rate per woman fParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
Metformin may leads to lower ovulation rate per woman Participants with BMI ≥ 30 kg/m2b compared with clomiphene citrate (low certainty).
Miscarriage · women with polycystic ovary syndrome
It is very uncertain whether metformin changes miscarriage rate per woman compared with clomiphene citrate (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher clinical pregnancy rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Menstrual frequency per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin may leads to higher menstrual frequency per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ovulation rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher ovulation rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Miscarriage · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Live birth rate per woman · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate showed no clear difference in live birth rate per woman compared with clomiphene citrate alone (low certainty).
Gastrointestinal adverse events · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher adverse events (gastrointestinal) per woman compared with clomiphene citrate alone (moderate certainty).
Clinical pregnancy rate · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher clinical pregnancy rate per woman compared with clomiphene citrate alone (moderate certainty).
Number of participantswith at least one recurrent adenoma · people with a history of colorectal adenomas
Dietary fibre (all study interventions) showed no clear difference in number of participantswith at least one recurrent adenoma compared with control (low certainty).
1 finding from 1 review
Number of participantswith more than one adenoma · people with a history of colorectal adenomas
Dietary fibre (all study interventions) showed no clear difference in number of participantswith more than one adenoma compared with control (low certainty).
1 finding from 1 review
Number of participantswith at least one adenoma 1 cm or greater · people with a history of colorectal adenomas
Dietary fibre (all study interventions) showed no clear difference in number of participantswith at least one adenoma 1 cm or greater compared with control (low certainty).
1 finding from 1 review
Number of participantsdiagnosed with colorectal cancer · people with a history of colorectal adenomas
Dietary fibre (all study interventions) may leads to higher number of participantsdiagnosed with colorectal cancer compared with control (low certainty).
1 finding from 1 review
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of % predicted FVC · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R · people with ALS/MND
1 finding from 1 review
Intervention not reported
Health‐related quality of life Short Form 12 Health Survey (SF‐12) · people with ALS/MND
1 finding from 1 review